NOTICIAS DIARIAS

Highlights

Complex Systemic Response To Infection Leading To Organ Failure

Complex Systemic Response To Infection Leading To Organ Failure

The researchers studying that the organ crosstalk leading; to a deeper understanding of sepsis. As Sepsis, a complex systemic response to infection leading to organ failure; is generally studying at the level of individual organs; this research has hinting at altering metabolic changes.
See news
Gastroenterology

Gastroesophageal Reflux Associated With Chronic Pain

The study find that the Gastroesophageal reflux (GERD) is associated with chronic, painful temporomandibular disorder pain in the temporomandibular joint and anxiety and poor sleep contribute to this association, according to a study in CMAJ (Canadian Medical Association Journal). Because Pain from temporomandibular disorder (TMD) affects about 13% of Canada's population. But Reflux is an uncomfortable condition in which stomach contents are regurgitate into the throat. Evidence indicates that anxiety, somatization and depression are link to GERD.
See news
Geriatrics

The Families are Mainly Responsible For Caring Elderly Parents

The researches find that the Both the men and women in the interviews were surprised that their aging parents suddenly needed them, Björk said. "It was quite a shock to many when they realized that they actually had help their parents. They felt it was unfair, in a way," she said. "It may be because they have grown accustomed to having healthy, independent parents and have believed that they will always be that way. But it may also be that they have been confident that this is something the welfare state will fix for them;" she said.
See news
Anesthesiology

Total Intravenous Anesthesia and Target-controlled Infusion in Children

The researches find that the Propofol administered in conjunction with an opioid such as remifentanil is used to provide total intravenous anesthesia for children. Drugs  give as infusion control manually by the physician or as automated target-controlled infusion that targets plasma or effect site. Smart pumps programmed with pharmacokinetic parameter estimates administer drugs to a preset plasma concentration.  A linking rate constant parameter (keo) allows estimation of effect site concentration.
See news
Nanoparticles Deliver Drugs With The Pinpoint Targeting

Nanoparticles Deliver Drugs With The Pinpoint Targeting

Discovering a new way to deliver drugs with the pinpoint targeting; As most of the pharmaceuticals must either be ingesting or injecting into the body to do their work. Either way, it takes some time for them to reach their intended targets; and they also tend to spread out to other areas of the body.
See news

‘Key Player’ Identified Gene To Psychiatric Condition

Scientists have identified a specific gene they believe could be a key player in the changes in brain structure; seen in several psychiatric conditions, such as schizophrenia and autism. The team from Cardiff University's Neuroscience and Mental Health Research Institute has found that the deletion of the gene CYFIP1 leads to thinning of the insulation; that covers nerve cells and is vital for the smooth and rapid communications between different parts of the brain. The new findings, published in the journal Nature Communications and highlighted in the journal Nature Reviews Neuroscience; throws new light on the potential cause of psychiatric conditions; and could ultimately point to new and more effective therapies. Though there are a number of genetic changes that can alter the risk of psychiatric disorders; one prominent change called Copy Number Variants (CNV) and involves the deletion of bits of DNA. Deletion of one specific gene Specifically, a CNV is where DNA deleted from one of the chromosome pairs. Work done in the world-leading Medical Research Council Centre for Neuropsychiatric Genetics; and Genomics at Cardiff has shown that people who have these deletions of DNA have a much higher chance of psychiatric disorder but as the deletions often contain many genes; it has so far a mystery as to exactly which genes contribute to the increased risk. But in their study the team focused on the deletion of one specific gene; CYFIP1, located in a precise location of chromosome 15, known as 15q11.2, which had already identified by the same team as an area with links to the biological abnormalities; associated with psychiatric disorder. However, using cutting-edge methods and growing brain cells where one copy of CYFIP1  missing; able to show that this was linked to abnormalities in myelin an insulating layer or sheath that forms around nerves in the brain. Moreover, the team were able to trace these abnormalities back to specific brain cells called oligodendrocytes; which are responsible for producing myelin sheaths. First author of the study Ana Silva; who carried out the work with colleagues as part of her Ph.D. studies, supported by the Welcome Trust, said: "What surprised us most was how much of the 15q11.2 deletion effects could be explained by a single gene effect. Physical and social environment "However, they know that the risk of suffering from a psychiatric condition influenced; by a whole host of factors related to both the physical and social environment and our genetic make-up. They believe that CYFIP1 is a key player in the damaging effects of the 15q11.2 deletion; and because they know what sort of brain functions this gene is involved in, they can use this knowledge to increase; our understanding of psychiatric disorder and potentially find new and more effective therapies." Lead author Professor Lawrence Wilkinson, Scientific Director of the Neuroscience; and Mental Health Institute at Cardiff University, said: "Cardiff has been at the forefront of identifying genetic risk factors for psychiatric conditions; and the challenge now is to make biological sense of the genetics to help us understand the disease pathology and design better treatments. "The work with CYFIP1 is an example of how genetic insights can guide research into biological mechanisms underlying dysfunction."

Fish Oil Supplements Have No Effect On Type 2 Diabetes

Omega-3 fats have little or no effect on risk of Type 2 diabetes; according to new research from the University of East Anglia. Increased consumption of omega 3 fats is widely promote globally because of a common belief that it will protect against; or even reverse, conditions such as diabetes. But a systematic review commissioned by the World Health Organization; and published today in the British Medical Journal, finds that omega 3 supplements offer no benefit. Despite over 58,000 participants randomize into long-term trials, and 4 % of those participants developing diabetes, the people who were randomised to consume more long-chain omega-3 fats (fish oils) had the same risk of diabetes diagnosis; as the control group who did not take more fish oil. Blood glucose, insulin and glycated haemoglobin; measures of how well our bodies handle sugars (glucose metabolism) and important measures of diabetes risk; also similar in people taking and not taking additional fish oils. There was a consistent lack of effect of fish oils (long-chain omega-3 fats); on any of these factors related to diabetes risk. However, there was some (weak) evidence that when people take high doses of fish oils; they may experience worsening glucose metabolism. Omega 3 is a type of fat. Small amounts are essential for good health and found in the food that we eat. The main types of omega 3 fatty acids are alpha¬linolenic acid (ALA); eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Omega-3 fats on diabetes ALA is normally found in fats from plant foods; such as nuts and seeds (walnuts and rapeseed are rich sources). EPA and DHA, collectively called long-chain omega 3 fats, are naturally found in fatty fish; such as salmon and fish oils including cod liver oil. Omega 3 fats, also readily available as over-the-counter supplements and they are widely bought and used. The research team assessed the effects of long-chain omega-3 fats, ALA, omega-6 and polyunsaturated fatty acids (PUFAs) taken as supplementary capsules; or via enriched or naturally rich foods. The systematic review combines the results of 83 randomized controlled trials involving 121,070 people; with and without diabetes, all of at least six months duration. Participants included men and women; some healthy and others with existing diabetes, from North America, South America, Europe, Australia and Asia; in studies published from the 1960s until 2018. The research assessed the effects of increasing long-chain omega-3 fats, ALA; omega-6 and polyunsaturated fatty acids (PUFAs) on diabetes and glucose metabolism. Participants randomly assigned to increase their polyunsaturated fats or to maintain their usual intake for at least six months. There was clearly no effect of increasing long-chain omega-3 fats on diabetes; but there was insufficient information from trials of ALA, omega-6 or total polyunsaturated fats to assess either protective or harmful effects. Heart disease, stroke or death The reviewers double-checked their data using sensitivity analyses. For example, they checked that the results did not alter when only the very highest quality trials included. They used subgrouping to check whether results differed with different doses of long-chain omega-3; or by trial duration. The results show that increasing long-chain omega-3 had little; or no effect on diabetes diagnosis or glucose metabolism, but high doses; at levels found in some supplements, could worsen glucose metabolism. Lead author Dr. Lee Hooper, from UEA's Norwich Medical School, said: "The previous research has shown that long-chain omega 3 supplements; including fish oils, do not protect against conditions such as heart disease, stroke or death. This review shows that they do not prevent or treat diabetes either. "Omega-3 supplements should not encourage for diabetes prevention or treatment. If people do choose to take supplementary fish oil capsules to treat or prevent diabetes; or to reduce levels of triglycerides in their blood, then they should use doses of less than 4.4 grams per day to avoid possible negative outcomes. "They would also have liked to find out whether taking more omega-3 might be useful in those people with low omega-3 intakes as giving more omega-3 is more likely to be useful in adults with low intakes. But unfortunately most trials did not report omega-3 intake levels of participants at the start of the trial, so we still do not know.

Cardiac Deaths Among Persons With Human Immunodeficiency Virus

The study finding that the heart failure patients with Human Immunodeficiency Virus; face higher risk of sudden cardiac death. The risk of sudden cardiac death (SCD) appears to be higher among heart failure patients who also have HIV infection, according to new findings. Data from San Francisco among patients with HIV; and without heart failure showing; that persons with HIV were at an elevated risk of sudden death. But by used data from a prospective observational registry; at Bronx-Lebanon Hospital Center of Icahn School of Medicine at Mount Sinai; in New York City, to analyze the incidence of SCD among people living with HIV (PHIV) hospitalizing with heart failure and the risk factors associated with it. They defined SCD, the primary outcome; as death within one hour of onset of symptoms if witnessed or within 24 hours of being observing alive; and asymptomatic if unwitnessing or unexpecting out-of-hospital death. The study included 2,149 individuals hospitalized with heart failure without an implantable cardioverter defibrillator (ICD), including 344 PHIV. Human immunodeficiency virus Compared with other patients, PHIV were more likely to have coronary artery disease; elevating pulmonary artery systolic pressure; cocaine use and co-infection with hepatitis C virus. During a median follow-up of 19 months, there were 191 SCDs, with a significantly higher rate among PHIV (21%); than among non-HIV-infecting individuals (6.4%), the researchers reporting. In a multivariable model, factors independently associated with SCD among PHIV included coronary-artery disease, lower CD4 count or non-suppressed viral load, cocaine use, non-prescription of beta-blockers, low left ventricular ejection fraction (LVEF); wider QRS and increased corrected QT duration. In stratified analyses, the SCD rate was significantly higher among PHIV than among non-HIV-infected patients with preserved LVEF (50% or higher), borderline LVEF (35-49%), or reduced LVEF (below 35%). HIV-uninfected women The SCD rate was also significantly higher among women with HIV than among HIV-uninfected women and higher among African Americans living with HIV than among non-African Americans living with HIV. Recognize that there are risk factors for sudden death which are unique to this group; Individuals with HIV are aging and are facing a 2-fold heightened risk for heart failure. Once individuals with HIV develop heart failure, their cardiac outcomes (sudden death and heart failure hospitalizations) are worse. We need to better understand why and come up with plausible ways of both reducing the risk for heart failure and improving outcomes in this at-risk population. But performing additional studies to better understand the pathophysiology behind the heightened risk of sudden death in HIV.

Ketamine Is A Dissociative Anesthetic Use In Human Anesthesia

The researches find that the A new study indicates that the antidepressant effects of ketamine may not be such, according to a paper published in Psychotherapy and Psychosomatics. The study investigates the hypothesis that depressed individual receiving ketamine infusions; associate feelings of lightness and floating which are a typical occurrence in the use of psychoactive-substance; with an antidepressant state. Therefore Ketamine is use by medical practitioners and veterinarians as an anaesthetic. It is sometimes use illegally by people to get high. Antidepressant effects of ketamine Ketamine can produce psychedelic effects, causing a person to see, hear, smell, feel or taste things that aren’t really there or are different from how they are in reality. When it’s sold illegally; ketamine usually comes as a white crystalline powder. It can also be make into tablets and pills, or dissolved in a liquid. A number of clinical trials and studies are currently being undertaken to assess ketamine as a treatment for depression; early indications are showing good results. Pharmacologically, ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, but at higher doses may also bind to the opioid mu and sigma receptors. This drug disrupts the neurotransmitter (brain chemical) glutamate. Glutamate is involve with learning, memory; emotion, pain recognition. It can exhibit sympathomimetic activity which can lead to rapid heart rate and elevated blood pressure. Ketamine is a dissociative anesthetic use in human anesthesia and veterinary medicine. Dissociative drugs are hallucinogens that cause a person to feel detached from reality. Depressed individuals receiving Much of the sold on the street has been divert from veterinarians’ offices. Ketamine’s chemical structure and mechanism of action are similar to those of PCP. In a systematic YouTube search of depressed individuals using ketamine infusions, 17 out of 62 testifiers (27.4%) spontaneously reported experiencing a sense of lightness or less heaviness that they associated with a reduction in depressive symptoms. This result is in contrast with the fact that a literature search did not find a single article that addressed the question if a ketamine-induced sense of lightness might be associated with antidepressant benefits for depressed individuals. Furthermore, compared to depressed individuals receiving electroconvulsive therapy (comparison group); but an analog systematic analysis of internet video testimonials shows that antidepressant-associate lightness is rarely report (4%). Authors suggested that future studies should focus on investigating the link between a subjective sense of lightness and antidepressant benefits suggesting a potential role could be played by the -induced opioid-system activation.

Proteins-Transport Discovery New Strategies For Treating Vision Loss

Many forms of vision loss stem from a common source: impaired communication between the eye and the brain. And at the root of all eye-to-brain communication are the hundreds of proteins generated by the retina's nerve cells. A new study from Scripps Research, which appears this month in Cell Reports, examines these proteins in unprecedented detail providing surprising; new insights into how visual signals distributed to different regions of the brain. The results are an important first step in understanding and eventually treating vision loss from glaucoma; multiple sclerosis or even trauma. More than 3.3 million Americans aged 40 years and older are either legally blind; or have visual impairments that can't be corrected with today's interventions; according to the Centers for Disease Control and Prevention. "Proteins are usually the targets of drugs so if you want to design; a drug that will help communication between the eye and the brain, it helps to know what proteins those drugs would target," says Hollis Cline, Ph.D., co-chair of Scripps Research's Department of Neuroscience; who led the research project. "This type of study was never possible before because it was not; feasible to see how these proteins move around the brain. The technology did not exist." Proteins are transported To create the technology, Cline's lab worked closely with the lab of John Yates III, Ph.D., a Scripps Research chemist who has pioneered new ways to use an analytical technique known as mass spectrometry; to study proteins and their functions. Using this new method developed over the course of several years Cline's team was able to "label" about 1,000 different types of proteins; that originate in the eye's retinal ganglion cells, and then watch how and where they travel in a living brain of a rat. Just as in human brains, the proteins transported via neuronal axons, which are long; threadlike nerve fibers that extend from the eye into the brain via the optic nerve. "The brain is an ensemble of very complicated architecture; and it is hard to separate every component and study the pieces individually," says Lucio Schiapparelli, Ph.D., a neuroscientist in Cline's lab and a lead author of the study. "Our methodology allowed us examine the visual system in a way that had not studied before so we could observe the molecules; independently and analyze their biochemistry." Going into the study, Cline said she was curious whether similar types of proteins; would travel to distinct targets within the brain. The retina projects proteins into more than 30 different areas of the central nervous system; but for the study, her team chose to evaluate the two major targets: the superior colliculus (which analyzes motion in the visual field; and controls goal-directed head and eye movements), and the lateral geniculate nucleus (which analyzes the shape of objects we see; and sends that information to a higher brain area, the visual cortex). Devastating eye diseases While previous studied identified various proteins produced in the retina; the ultimate destination of these proteins was largely unknown. The optic nerve was an especially important focus of study; implicated in so many devastating eye diseases. "They were surprised right from the start to find proteins in the axons of the optic nerve; that everybody previously thought would be functioning only in the eye," Cline says. "These are proteins that are usually in the nucleus of a cell; but we found them far, far away from the nucleus, participating in some form of communication." This finding, Cline says, has already fueled new research on how these proteins may influence health and disease. Because this type of neuronal protein exists in other parts of the body; it may play a role in other nerve-cell communication disorders such as Charcot-Marie-Tooth disease. The optic nerve is the information highway from the eye to the brain; sending signals to different destinations. But the team discovered that that similar proteins did not always share a common destination. Rather, many proteins were transported preferentially to one brain region; while some were transported to all of the regions studied.

Scientists Discover Why Brown Fat Is Good For People’s Health

Rutgers and other scientists have discovered how brown fat; also known as brown adipose tissue, may help protect against obesity and diabetes. Their study in the journal Nature adds to our knowledge about the role of brown fat in human health; and could lead to new medications for treating obesity and type 2 diabetes. Branched-chain amino acid (BCAA; valine, leucine and isoleucine) supplementation; is often beneficial to energy expenditure; however, increased circulating levels of BCAA are linked to obesity and diabetes. The mechanisms of this paradox remain unclear.  Brown fat is considered a heat organ. People have a few grams of it in areas including the neck; collarbone, kidneys and spinal cord. When activated by cool temperatures; brown fat uses sugar and fat from the blood to generate heat in the body. Mystery about brown fat The study found that brown fat could also help the body filter; and remove branched-chain amino acids (BCAAs) from the blood. BCAAs (leucine, isoleucine and valine) are found in foods like eggs; meat, fish, chicken and milk, but also in supplements used by some athletes and people who want to build muscle mass. In normal concentrations in the blood; these amino acids are essential for good health. In excessive amounts, they are link to diabetes and obesity. The researchers found that people with little or no brown fat have reduced ability to clear BCAAs from their blood; and that may lead to the development of obesity and diabetes. The study also solved a 20-plus year mystery about brown fats: how BCAAs enter the mitochondria that generate energy and heat in cells. The scientists discovered that a novel protein (called SLC25A44); controls the rate at which brown fat clears the amino acids from the blood and uses them to produce energy and heat. Mildly cold temperatures "The study explains the paradox that BCAA supplements can potentially benefit those with active brown fats; such as healthy people, but can be detrimental to others, including the elderly, obese and people with diabetes," said co-author Labros S. Sidossis; a Distinguished Professor who chairs the Department of Kinesiology and Health in the School of Arts and Sciences at Rutgers University-New Brunswick. Researchers next need to determine whether uptake of BCAAs; by brown fat can controlled by environmental factors such as exposure to mildly cold temperatures (65 degrees Fahrenheit) or consumption of spicy foods or by drugs. This could improve blood sugar levels that linked to diabetes and obesity, Sidossis said.

Party Increases Risk Of Drug Related Emergencies

People who frequent electronic dance music (EDM) parties often use multiple drugs simultaneously and experience adverse effects with some ending up in the emergency department, say researchers at New York University School of Medicine and Rutgers University. The study, published in the International Journal of Drug Policy, is the first to survey adverse effects; with use of dozens of different drugs and could improve treatment for drug relate emergencies. Drug relate emergencies The researchers survey 1,029 people ages 18 to 40 as they entered EDM parties in New York City in 2018. They were asked about their use of drugs including opioids, alcohol, marijuana and other common illegal drugs over the past year; whether they had experience adverse effects after using the drugs, and if they sought medical care. Adverse effects were define as harmful or very unpleasant effects; which users were concerned about their immediate safety. The study estimates that one-third of people at these events; commonly held at night clubs and large outdoor dance festivals; have experience a drug-related adverse effect over the past year. Of these, 40% experience an adverse effect on more than one occasion and 5% experience adverse effects on four or more occasions. Also, the more frequently people attend these parties; the more likely they were to experience an adverse drug reaction. The study also found that two thirds of adverse effects involve alcohol; more than one third involve marijuana; also 15% involved Ecstasy, commonly referred to as "Molly" when in powder or crystal form. "Alcohol use was with the greatest number of adverse outcomes,; perhaps due to its ubiquitous nature and its impact on judgment," said study co-author Lewis Nelson; a professor of emergency medicine at Rutgers New Jersey Medical School. Emergency department About 37% of adverse effects occur after marijuana use; also more than one third of these ate edible marijuana. "This may be the result of consuming too many edibles to accelerate the high or to experience a more intense or prolong high. The increasing, and unpredictable, potency of cannabis also contributes to the difficulty in controlling the dose consume" Nelson said. One-fifth of those using Ecstasy or Molly reported an adverse effect. Of these, 14% felt the need to visit an emergency department, and one-half of those people did seek such help. Prescription opioids were used less than other drugs; however, 41% of nonmedical users had experienced an adverse reaction, with 14% making a trip to an emergency department. "Opioids are a high-risk group of drugs, particularly when used in combination with alcohol or other drugs," said Nelson. "Our finding about 'bath salt' use leading to emergency room visits is particularly alarming because we've been finding that a lot of people who think they're using Molly are often using 'bath salts' without realizing it," Palamar add. "While we couldn't deduce to what extent adverse effects occurred at these parties, these are high-risk venues due to a combination of drug use and environmental factors," he continued. "Dancing for hours, hot temperatures, and dehydration appear to exacerbate the risk for adverse effects among those who use drugs."